FindTrial
Sign In

Effect of Molecular, Pathological and Clinical features in choosing best treatment for Endometrial Cancer: A registry from multiple Asian institutes

Impact of Molecular Pathological And Clinical features for adjuvant Treatment selection in Endometrial cancer: Multicentric Asian Registry (IMPACT-Endo-Asia) - IMPACT-Endo-Asia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/086463
Enrollment
300
Registered
2025-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C541- Malignant neoplasm of endometrium

Interventions

Intervention1: NIL: NIL

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who were diagnosed to have Endometrial Cancer and have access to standard histopathological reports and availability of treatment decisions.

Exclusion criteria

Exclusion criteria: Patients with final histopathological diagnosis of any other gynecological malignancy other than Endometrial Cancer and its subtypes.

Design outcomes

Primary

MeasureTime frame
The retrospective study and data analysis offer a promising opportunity to pave the way for a prospective study in the future, thereby providing an avenue to streamline the adjuvant treatment decisions for endometrial cancer patients. By adopting a standardized treatment approach, we can work towards improving patient outcomes and enhancing the quality of care.Timepoint: 3 years—

Secondary

MeasureTime frame
NoneTimepoint:—

Countries

India, Indonesia, Philippines, Thailand

Contacts

Public ContactDr Supriya Chopra

ACTREC Tata Memorial Centre

supriyasastri@gmail.com9930958309

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026